JP2018522049A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522049A5
JP2018522049A5 JP2018505714A JP2018505714A JP2018522049A5 JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5 JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5
Authority
JP
Japan
Prior art keywords
hydrate
pharmaceutically acceptable
acceptable salt
formula
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522049A (ja
JP6815383B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043676 external-priority patent/WO2017023584A1/en
Publication of JP2018522049A publication Critical patent/JP2018522049A/ja
Publication of JP2018522049A5 publication Critical patent/JP2018522049A5/ja
Application granted granted Critical
Publication of JP6815383B2 publication Critical patent/JP6815383B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505714A 2015-08-03 2016-07-22 がん処置のための組み合わせ療法 Expired - Fee Related JP6815383B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562200549P 2015-08-03 2015-08-03
US201562200556P 2015-08-03 2015-08-03
US201562200545P 2015-08-03 2015-08-03
US62/200,556 2015-08-03
US62/200,549 2015-08-03
US62/200,545 2015-08-03
US201562201009P 2015-08-04 2015-08-04
US62/201,009 2015-08-04
US201562235102P 2015-09-30 2015-09-30
US62/235,102 2015-09-30
PCT/US2016/043676 WO2017023584A1 (en) 2015-08-03 2016-07-22 Combination therapies for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171578A Division JP2021001237A (ja) 2015-08-03 2020-10-09 がん処置のための組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2018522049A JP2018522049A (ja) 2018-08-09
JP2018522049A5 true JP2018522049A5 (enExample) 2019-09-05
JP6815383B2 JP6815383B2 (ja) 2021-01-20

Family

ID=56555867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018505714A Expired - Fee Related JP6815383B2 (ja) 2015-08-03 2016-07-22 がん処置のための組み合わせ療法
JP2020171578A Pending JP2021001237A (ja) 2015-08-03 2020-10-09 がん処置のための組み合わせ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171578A Pending JP2021001237A (ja) 2015-08-03 2020-10-09 がん処置のための組み合わせ療法

Country Status (8)

Country Link
US (1) US20180207164A1 (enExample)
EP (1) EP3331531A1 (enExample)
JP (2) JP6815383B2 (enExample)
AU (1) AU2016304172A1 (enExample)
CA (1) CA2994265A1 (enExample)
HK (1) HK1255939A1 (enExample)
TW (1) TW201717953A (enExample)
WO (1) WO2017023584A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
EP4101468A4 (en) * 2020-02-05 2024-02-28 Carna Biosciences, Inc. Anticancer agent composition
WO2024037910A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
CN118373787A (zh) * 2024-04-26 2024-07-23 苏州九鹭生物医药有限公司 一种氘代n-酰基磺酰胺类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3919079A1 (en) * 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
US20160287592A1 (en) * 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
KR20160013204A (ko) * 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
CA2926893C (en) * 2013-11-07 2022-04-12 F. Hoffmann-La Roche Ag Combination therapy of an anti cd20 antibody with a btk inhibitor
TWI662037B (zh) * 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
RS63364B1 (sr) * 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法

Similar Documents

Publication Publication Date Title
JPWO2022014639A5 (enExample)
JP2019501133A5 (enExample)
JP2014517050A5 (enExample)
JP2015535247A5 (enExample)
JP2014513136A5 (enExample)
JP2015528471A5 (enExample)
KR102634247B1 (ko) 다발성 골수종을 치료하기 위한 약물 병용물
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2014505735A5 (enExample)
JP2016536286A5 (enExample)
JP2014500295A5 (enExample)
JP2012530779A5 (enExample)
JP2008521928A5 (enExample)
JP2013507415A5 (enExample)
JP2017526677A5 (enExample)
JP2015524472A5 (enExample)
JP2015536986A (ja) 併用療法
JP2017529382A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2014525454A5 (enExample)
JP2014505107A5 (enExample)
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
JP2016529285A5 (enExample)
JP2018534288A5 (enExample)
JP2016522254A5 (enExample)